This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
This event has ended
At the 2017 European Lung Cancer Conference (ELCC), Boehringer Ingelheim hosted a satellite symposium entitled ‘Sharing our knowledge in NSCLC: case interchange of real-world experience.’ The event was chaired by Prof. Rolf Stahel, and included presentations from Dr Noemí Reguart, Prof. David Gandara and Dr Maximilian Hochmair.
Please see below for the presentations from this symposium as well as details of other BI activities at ELCC 2017.
The full ELCC 2017 programme can be found here.
ELCC symposium presentations:
Making the first decision: EGFR mutation-positive NSCLC in the advanced setting
Dr Noemi Reguart
Understanding choice in the treatment of squamous NSCLC: when should TKIs be considered?
Dr David Gandara
Antiangiogenic agents beyond first-line: matching patients with treatments
Dr Maximilian Hochmair
Afatinib* (A) plus cetuximab (C) in the treatment of patients (pts) with NSCLC: the story so far. (Presentation #86O).
Afatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): analysis of time to treatment failure and impact of afatinib dose adjustment. (Presentation #100P)
LUX-Lung 8 phase III trial: analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung. (Presentation #102P)
A non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib** according to the approved label (LUME-BioNIS). (Presentation #139TiP)
LUME-Meso: Randomised Phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM). (Presentation #170TiP)
First-line afatinib for advanced EGFRm+ NSCLC: analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials. (Presentation #92PD)
Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7). (Presentation #93PD)
Didn’t make ELCC? Find out upcoming oncology events.
Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.
*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.
**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue